Cidara Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 12.72 million compared to USD 40.74 million a year ago. Net loss was USD 8.17 million compared to net income of USD 14.98 million a year ago. Basic loss per share from continuing operations was USD 1.8 compared to basic earnings per share from continuing operations of USD 3.4 a year ago. Diluted loss per share from continuing operations was USD 1.8 compared to diluted earnings per share from continuing operations of USD 3.4 a year ago.
For the nine months, revenue was USD 46.32 million compared to USD 54.07 million a year ago. Net loss was USD 17.32 million compared to USD 16.42 million a year ago. Basic loss per share from continuing operations was USD 4 compared to USD 4.8 a year ago. Diluted loss per share from continuing operations was USD 4 compared to USD 4.8 a year ago.